FFNS 110 mcg QD | Placebo | ||
---|---|---|---|
(N=53) | (N=49) | ||
Baseline | |||
Mean (SE) | 6.7 (0.17) | 6.4 (0.17) | |
Weeks 1 – 4 | 4.4 (0.25) | 4.4 (0.24) | |
Mean (SE) | |||
Week 1 | |||
Mean change (SE) | -1.6 (0.22) | -1.3 (0.19) | |
Week 2, n | 53 | 49 | |
Mean change (SE) | -2.1 (0.26) | -1.8 (0.28) | |
Week 3, n | 51 | 47 | |
Mean change (SE) | -2.5 (0.29) | -2.4 (0.28) | |
Week 4, n | 49 | 46 | |
Mean change (SE) | -2.9 (0.30) | -2.8 (0.29) | |
Weeks 1 – 4 | |||
Mean change (SE) | -2.2 (0.24) | -2.0 (0.24) | |
Least squares mean change (SE) | -2.17 (0.23) | -2.10 (0.25) | |
Least squares mean difference | -0.065 | ||
p-value | 0.845 |